The delivery of inhaled pulmonary vasodilators (iPVD) and its ability to affect pulmonary vascular resistance (PVR) without impacting the systemic vasculature has produced improvements in both morbidity and mortality in patients.
Today, targeted PVR therapy comes in several forms. To appreciate the current state of iPVDs, we will review the current knowledge of vascular tone modulation and the available pharmacological agents used.
Therefore, considerations in providing this service should include the individual needs of the patient population, the environment of use, and identified outcomes desired.
